Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Home Newsfeeds Guggenheim Reiterates Buy on Larimar Therapeutics, Maintains $12 Price Target

Guggenheim Reiterates Buy on Larimar Therapeutics, Maintains $12 Price Target

Guggenheim analyst Yatin Suneja reiterates Larimar Therapeutics (NASDAQ:LRMR) with a Buy and maintains $12 price target.

March 15, 2023

1 minute read

Guggenheim analyst Yatin Suneja reiterates Larimar Therapeutics (NASDAQ:LRMR) with a Buy and maintains $12 price target.

Piper Sandler Maintains Overweight on Olin, Lowers Price Target to $68

September 21, 6:40 AM

Piper Sandler analyst Charles Neivert maintains Olin (NYSE:OLN) with a Overweight and lowers the price target from $73 to $68.

December 9, 6:27 AM

Citigroup analyst Spiro Dounis initiates coverage on Plains All American (NASDAQ:PAA) with a Buy rating and announces Price Target of $14.

January 6, 9:42 AM

UBS analyst Andrew Mok maintains CareMax (NASDAQ:CMAX) with a Buy and lowers the price target from $10 to $6.

July 18, 3:10 PM

Within the last quarter, Workday (NASDAQ:WDAY) has observed the following analyst ratings: